Semaglutide
Ozempic / Wegovy Analog
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant efficacy in metabolic research. It works by mimicking the GLP-1 hormone, which stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Our pharmaceutical-grade semaglutide is produced via solid-phase peptide synthesis (SPPS) with rigorous quality control at every stage.
Key Benefits
Available Sizes
B2B Wholesale Only · For Research Use Only · COA Provided with Every Order
Product Description
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has demonstrated significant efficacy in metabolic research. It works by mimicking the GLP-1 hormone, which stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Our pharmaceutical-grade semaglutide is produced via solid-phase peptide synthesis (SPPS) with rigorous quality control at every stage.
Amino Acid Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH₂
Molecular Information
Request a Wholesale Quote
Fill out the form and our B2B team will respond within 24 hours with pricing, MOQ, and availability for Semaglutide.
Related Research
Peer-reviewed scientific literature on Semaglutide from PubMed, NEJM, The Lancet, and other authoritative sources.
Research Use Only. The following citations are provided for informational purposes and represent independent scientific research. These studies do not constitute medical advice or claims about our products. All products are sold for research purposes only and are not intended for human use.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 Trial)
Wilding JPH, Batterham RL, Calanna S, et al.
New England Journal of Medicine, 384: 989–1002 (2021)
Participants receiving semaglutide lost a mean of 14.9% of body weight vs. 2.4% with placebo (p<0.001). 86.4% of semaglutide participants achieved ≥5% weight loss.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial)
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.
New England Journal of Medicine, 389: 2221–2232 (2023)
Semaglutide reduced the risk of major adverse cardiovascular events by 20% (HR 0.80; 95% CI 0.72–0.90; p<0.001) compared to placebo over a mean follow-up of 39.8 months.
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials
Ryan DH, Lingvay I, Colhoun HM, et al.
Obesity, 28: 1050–1061 (2020)
The STEP program demonstrated consistent and clinically meaningful weight reductions with semaglutide 2.4 mg across diverse patient populations, establishing a new benchmark for pharmacological obesity treatment.
Citations sourced from PubMed / NCBI, New England Journal of Medicine, The Lancet, Nature, and other peer-reviewed publications. DOI links lead to original publisher pages.
Related Products
Tirzepatide
Dual GIP/GLP-1 receptor agonist. Widely used in metabolic and weight management research.
Retatrutide
Triple-agonist candidate for advanced metabolic regulation and adiposity research.
Cagrilintide
Long-acting amylin analog peptide used in appetite and obesity-related studies.